Seattle Genetics Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Cowen Raises Price Target on Seattle Genetics (SGEN) Following 2Q15
July 31, 2015 8:46 AM EDTCowen reiterated a Market Perform rating on Seattle Genetics (NASDAQ: SGEN), and raises the price target to $40.50 (from $34.00), following 2Q15 results. SGEN posted Adcetris sales of $55.1M for 2Q15, ahead of consensus $50.9M estimates.
Analyst Boris Peaker commented, "SGEN reported 2Q15... More
Seattle Genetics (SGEN) Misses Q2 EPS by 12c, Offers Outlook
July 30, 2015 4:11 PM EDTSeattle Genetics (NASDAQ: SGEN) reported Q2 EPS of ($0.38), $0.12 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $77.1 million versus the consensus estimate of $77.97 million.
2015 Financial Outlook
Seattle Genetics anticipates that 2015 revenues from ADCETRIS net product... More
